The Aurora Kinases in Cell Cycle and Leukemia

Benjamin Goldenson and John D. Crispino
Northwestern University, Chicago IL 60611

Abstract

The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C (AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and AURKB) and meiosis (AURKC). Since their discovery nearly twenty years ago, Aurora kinases have been studied extensively in cell and cancer biology. Several early studies found that Aurora kinases are amplified and overexpressed at the transcript and protein level in various malignancies, including several types of leukemia. These discoveries and others provided a rationale for the development of small molecule inhibitors of Aurora kinases as leukemia therapies. The first generation of Aurora kinase inhibitors did not fare well in clinical trials, owing to poor efficacy and high toxicity. However, the creation of second generation, highly selective Aurora kinase inhibitors has increased the enthusiasm for targeting these proteins in leukemia. This review will describe the functions of each Aurora kinase, summarize their involvement in leukemia and discuss inhibitor development and efficacy in leukemia clinical trials.

STRUCTURE AND REGULATION OF THE AURORA KINASES

The Aurora kinases are highly conserved serine/threonine kinases that regulate chromosomal alignment and segregation during mitosis and meiosis. Aurora A, B and C are comprised of 403, 344, and 309 amino acids, respectively. The proteins contain an N-terminal domain composed of 39 to 129 residues, a protein kinase domain and a C-terminal domain of 15 to 20 residues (Figure 1). Overall, the three Aurora kinases share high sequence identity. The kinases also share high homology between species and are evolutionarily ancient with Aurora A sharing 82% sequence identity between the human and rodent genes. They also share common ancestral genes in Drosophila and yeast. The functional similarity between Aurora A and B has been demonstrated by experiments showing that a single amino acid change in Aurora A, G198N, can convey an Aurora B kinase-like activity. However, the N-terminal domains of Aurora A, B and C share little sequence identity and confer unique protein–protein interaction abilities among the Aurora kinases.
The activity of Aurora kinases is regulated at multiple levels. Aurora A, B and C all contain a key threonine, named the T-loop residue, within their kinase domains that must be phosphorylated to allow for kinase activity. This occurs via autophosphorylation of the T-loop residue T288 (Aurora A), T232 (Aurora B) or T195 (Aurora C), which is driven by clustering of kinase molecules 5–9. Transcription of Aurora kinases, another mode of their control, is cell cycle-regulated. Aurora A mRNA typically peaks at G2/M with the protein expression peaking slightly later 5, 10. The promoter of Aurora A contains specific sequences required for transcription in the G2 phase of the cell cycle 10–12. The same is true for Aurora B: the level of this protein is cell cycle regulated and its activity peaks just after that of Aurora A 5. The three kinases are differentially expressed at high levels in rapidly dividing tissues such as hematopoietic cells (A and B), germ cells (C only) 13. Conversely, Aurora kinase expression is low or absent in most adult tissues due to their lower rates of proliferation 5.

Aurora kinase degradation is also highly regulated. All three family members contain destruction boxes (D-boxes) recognized by the multi-subunit E3-ubiquitin ligase anaphase promoting complex/cyclosome (APC/C), which mediates their proteasomal degradation (Figure 1). The APC/C, in conjunction with its specificity factor cdc20 homolog 1 (Cdh1), ubiquitylates Aurora A and targets it for degradation during mitotic exit 7, 14–20. Of note, the D-boxes are not sufficient for APC/C mediated ubiquitylation: Aurora A degradation is also dependent on Cdh1 20. Moreover, in addition to its D-boxes, Aurora A contains a KEN degradation motif and an N-terminal D-Box-activating motif 14, 18, 21. Other regulators of Aurora kinase degradation have been identified, such as Cdc4/Fbxw7, checkpoint with forkhead and ring finger domain (Chfr), and Aurora A interacting protein 1 22–24. Aurora B contains the same D-Box as Aurora A, but it is primarily degraded by proteasome alpha-subunit C8 in a proteasome-dependent manner 25.

FUNCTIONS OF THE AURORA KINASES

Although all three Aurora kinases are involved in cell division, the specific functions of each kinase vary. Aurora A, but not B or C, regulates centrosome maturation and separation and bipolar spindle assembly. Aurora B controls cytokinesis and chromosome bi-orientation as a member of the chromosome passenger complex. Aurora C coordinates meiotic spindles in spermatogenesis, while also cooperating with Aurora B to regulate mitotic chromosome dynamics 26, 27.

Aurora A Regulates Multiple Facets of Mitosis

The major function of Aurora A is to coordinate centrosome maturation, bipolar spindle assembly and chromosome separation (Figure 2). Aurora A is also important in the regulation of the spindle checkpoint and its activity contributes to the mitotic checkpoint response 28, 29. The spindle checkpoint network inhibits the activity of the APC/C and subsequent sister chromatid separation and anaphase until all chromosomes have achieved proper bipolar attachment to the mitotic spindle 30.

The expression, localization and activity of Aurora A are consistent with its function as a centrosomal kinase. Aurora A levels are low during G1/S phase, but increase in G2, with
both function and expression peaking in early M phase \(^5, 10, 31\). With respect to localization, it is found at the centrosome in mitotic cells from late S and G2 until telophase, but also localizes to the spindle throughout mitosis \(^10, 31–33\). Functionally, Aurora A regulates the progression of mitosis by phosphorylation of multiple substrates, and it promotes mitotic entry by controlling activation of Cyclin-B/Cdk-1 \(^34–36\). Aurora A also activates Polo-like kinase-1 (Plk-1) in G2 through direct phosphorylation of Plk-1 \(^37, 38\). Other cofactors and substrates include ajuba, enhancer of filamentation 1, BORA, TPX2, PLK-1, astrin, growth arrest and DNA damage-inducible 45\(\alpha\), transforming acidic coiled-coil containing protein 3 (TACC3) and centrosomin \(^39, 40\). Binding of Aurora A to TPX2 causes it to adopt an active conformation and also prevents dephosphorylation of Thr288 on Aurora A by protein phosphatase 1 \(^41\). PLK-1, which is also implicated in centrosome maturation, is involved in targeting Aurora A to centrosomes \(^42, 43\). Both PLK1 and CDK11 are required for Aurora A recruitment and centrosome maturation \(^40, 44, 45\). Other important functional interactions include the phosphorylation of LATS2, NDEI1 and TACC3 by Aurora A to enforce their recruitment to the centrosome and to promote centrosome maturation \(^46–48\).

**Aurora B Regulates Chromosome Condensation, the Spindle Checkpoint and Cytokinesis**

Aurora B provides catalytic activity to the chromosome passenger complex (CPC). The CPC, which also consists of survivin, borealin and INCENP, localizes to the kinetochores and centromeres from prophase to metaphase and then relocates to the cleavage furrow and midbody during cytokinesis \(^26, 49\). One function of Aurora B is to phosphorylate chromatin proteins such as histone H3 to aid in mitotic chromosome condensation. Another is to contribute to the spindle checkpoint: Aurora B phosphorylates the microtubule depolymerase mitotic centromere-associated kinesin (MCAK) to target it to kinetochores where it functions to correct any incorrect kinetochore attachments to the spindle \(^50–52\). Finally, Aurora B is essential for proper cytokinesis; in its absence the two daughter cells remain attached to each other through bridges of cytoplasm, the chromosomes missegregate and binucleate daughter cells form \(^49, 53–55\). Aurora B phosphorylation of MgcRacGAP, a GTPase-activating protein, activates its activity towards RhoA and thus promotes cytokinesis \(^56, 57\).

**Aurora C is required for spermatogenesis**

Less is known about Aurora C compared to the other Aurora kinases. Aurora C expression is restricted to the testis, but is aberrantly expressed in various cancer cell lines \(^58, 59\). It has been reported to be a chromosome passenger protein with similar localization as Aurora B \(^60\). Aurora C and Aurora B may have similar functions, as evidenced by the fact that Aurora C can rescue the phenotypes of Aurora B depleted cells \(^61, 62\). Aurora C is required for spermatogenesis and oocyte development: its deficiency causes cytokinesis failure in meiosis I resulting in the production of large polyploid oocytes in mice \(^63\). Mutations in Aurora C have been shown to cause infertility in humans, however, these individuals display no other obvious phenotype, supporting the idea that Aurora C is not required in somatic cells \(^63, 64\).
Loss of Function Studies

Several cell based and murine knockout and conditional deletion studies have provided information on the requirements for the Aurora kinases. Knockdown of Aurora A using siRNA, disruption of its activity with blocking antibodies or inhibition with small molecules all cause defects in many mitotic processes, including centrosome maturation and chromosome separation, mitotic spindle pole organization, centriole function, microtubule stability and cell cycle progression \(^{29, 34, 35, 37, 65-70}\). Of note, germline deficiency of *Aurka* results in early embryonic lethality before the morula develops due to a defect in mitotic spindle assembly \(^{71, 72}\). A conditional knockout study expanded on these results and showed that loss of *Aurka* in the visceral endoderm and epiblast leads to apoptosis and lethality at embryonic day 9.5 \(^{73}\). Studies with Aurora A deficient cell lines showed that in the absence of the kinase the spindle checkpoint detects the failure to align chromosomes and arrests the cells in mitosis. However, the Aurora A deficient cells can escape the arrest and exit mitosis with segregation errors. The escaped cells then face a second checkpoint in G1: here cells with competent p53 arrest in G1 and die while cells without functional p53 enter S phase and progress through the cell cycle \(^{74}\). Knockdown of Aurora B by RNAi shows that Aurora B is required for histone H3 phosphorylation during chromosome condensation and for cytokinesis \(^{75}\). In contrast to Aurora A, *Aurkb* null embryos implant normally. However, defects appear later in embryonic development due to the decrease in Aurora C expression in somatic tissues post-implantation. Similarly, conditional deletion of Aurora B in somatic cells that do not express Aurora C results in chromosomal segregation and alignment errors \(^{76}\). *Aurkb* null cells exit mitosis with segregation errors due to a failure to align chromosomes and have defects in cytokinesis that result in binucleate cell formation. Cells lacking both Aurora A and Aurora B (*Aurka^{-/-}Aurkb^{-/-}*) exit mitosis without completing anaphase \(^{74}\). In contrast to the phenotypes of *Aurka* and *Aurkb* mutants, *Aurkc* knockout mice appear normal other than defects in male fertility \(^{63}\).

AURORA KINASES IN CANCER AND LEUKEMIA

The Aurora kinases are overexpressed in a wide range of human cancers including several forms of leukemia. For instance, multiple studies have examined Aurora kinase expression in AML and found that blasts overexpress Aurora A and Aurora B compared to control CD34+ cells. This overexpression of Aurora A and Aurora B is associated with unfavorable cytogenetic abnormalities and other adverse factors such as a high white blood cell count \(^{77, 78}\).

Aurora A

The *AURKA* gene is located within a region of chromosome 20q13 that is amplified in many malignancies and the Aurora A F31L polymorphism is associated with an increased risk for esophageal, ovarian, non-small-cell lung, and breast cancers \(^{79, 80}\). Whether overexpression of Aurora A can promote tumorigenesis on its own is controversial. Some studies have found that Aurora A can drive transformation and tumors in nude mice \(^{5, 6, 31}\). In contrast, other studies suggest that overexpression alone is not sufficient to drive oncogenesis \(^{81}\). Instead, additional mutations may be required to cause malignant transformation. For
example, overexpression of Aurora A with activated Ras signaling was sufficient to promote transformation \(^{31},^{82}\).

The contributions of Aurora A to oncogenesis likely stem from its role in chromosome segregation. Defects in this process due to abnormal Aurora A function or expression cause aneuploidy and genetic instability, conditions that are associated with tumorigenesis. For instance, centrosome amplification caused by Aurora A overexpression induces multipolar spindles. Aurora A malfunction can also cause defects in the separation of centrosomes triggering the formation of a monopolar spindle, leading to abortive mitosis and ultimately the formation of tetraploid cells \(^{83},^{84}\). Moreover, Aurora A overexpression disrupts the proper assembly of the mitotic checkpoint complex at the level of the Cdc20–BubR1 interaction \(^{85}\). Finally, overexpression of Aurora A disrupts spindle checkpoint activation by paclitaxel and nocodazole treatment, causing the cells to become resistant to these chemotherapy drugs \(^{81}\).

One other possible mechanism by which Aurora A amplification could lead to tumor formation is via degradation of the tumor suppressor p53. Aurora A directly phosphorylates p53 to control its stability and transcriptional activity \(^{86},^{87}\). Overexpression of Aurora A leads to increased p53 degradation, while its amplification shows a clear correlation with p53 mutational status \(^{87},^{88}\). Inhibition of Aurora A in cells with wild type p53 results in apoptosis while its inhibition in cells lacking or with mutant p53 induces polyploidization \(^{89}\).

**Aurora B and Aurora C**

Aurora B is also overexpressed in many primary tumors, resulting in multinucleation and polyploidy of human cells \(^{90},^{91}\). Yet, unlike transformation mediated by Aurora A, overexpression of an inactive form of Aurora B results in multinucleation and polyploidy, indicating that kinase activity is not required for these malignant phenotypes \(^{5}\). Supporting the classification of Aurora B as a cancer promoting gene, its overexpression induced tetraploidy of murine epithelial cells and tumorigenesis in recipient mice \(^{15},^{91}\). Another study found that overexpression of Aurora B induced metastasis after implantation of tumors in nude mice \(^{92}\). Finally, p53 deficiency caused cells overexpressing Aurora B to form more aggressive tumors than those with wild-type p53 \(^{92}\). How Aurora B kinase overexpression facilitates tumorigenesis is an interesting question. It is likely that tetraploidy and subsequent genomic instability, which result from high levels of Aurora B, rather than purely its overexpression, leads to tumorigenesis. Indeed, tetraploidy has been shown to increase the frequency of chromosomal alterations and promote tumorigenesis of p53 deficient cells \(^{93}\).

Aurora C is aberrantly expressed in cancer cell lines \(^{94}\). One study showed that its overexpression induced abnormal cell division resulting in centrosome amplification, multinucleation and increased proliferation \(^{95}\). In another study, cells overexpressing Aurora C formed foci of colonies on soft agar, and transplantation of these cells induced tumor formation when injected into nude mice \(^{96}\).
Aurora Kinases in Megakaryocytes and Acute Megakaryoblastic Leukemia

Megakaryocytes are one of the few cell types that undergo repeated rounds of the cell cycle without cytokinesis. Previous studies have demonstrated that the cells progress through mitosis with nuclear envelope breakdown and chromosome condensation, but fail to complete mitosis (Figure 3). More recent studies have demonstrated that megakaryocytes progress to formation of a cleavage furrow, but the furrow regresses before cell division in polyploid megakaryocytes. With respect to Aurora kinases, several studies have examined Aurora B localization and function in megakaryocytes. All studies agree that Aurora B is expressed and localized normally during prophase in megakaryocytes. However, one group found that Aurora B is downregulated in murine megakaryocytes and that transgenic mice overexpressing Aurora B exhibit increased megakaryocyte numbers and slightly decreased ploidy levels. On the other hand, a different group found that Aurora B is present, appropriately localized and functional in endomitosis. This was similar to a third study that showed that Aurora B is normally expressed and properly localized during the human megakaryocyte endomitotic process. However, the appropriately localized, functional Aurora B did not prevent furrow regression in megakaryocytes. Aurora A was also found to be expressed and localized appropriately in megakaryocytes.

One rare subtype of leukemia that has a special involvement with the Aurora kinases is acute megakaryocytic leukemia (AMKL). In AMKL, immature megakaryocytes fail to exit the proliferative cell cycle, become polyploid or undergo terminal differentiation. The three major subgroups of AMKL are infants with Down syndrome (DS-AMKL), children without DS (non-DS AMKL) and adults (adult AMKL). In DS-AMKL, trisomy 21 and somatic mutations in the GATA1 gene are found in nearly every patient. In addition, mutations in the cohesin complex, epigenetic regulators and signaling cascades are seen in this malignancy. Various chromosomal abnormalities, such as t(1;22)(p13;q13), which leads to expression of the OTT-MAL fusion protein, inv(16) leading to the CBFA2T3-GLIS2 fusion, and t(5;11) leading to the NUP98/JARID1A fusion are associated with non-DS pediatric AMKL. Pathways that are mutated in adults with AMKL include JAK/STAT, c-MPL, c-kit and FLT3.

Recently, we demonstrated that Aurora A is an important and novel target in AMKL, and that Aurora kinase inhibitors are effective therapies in multiple pre-clinical models of this malignancy. The initial hypothesis of the project was that small-molecule inducers of polyploidization would force malignant megakaryocytes to exit the proliferative cell cycle and undergo endomitosis and terminal differentiation. To test this idea, we leveraged an integrated screening approach that included chemical, proteomic and small interfering RNA (siRNA) screens to identify compounds and their cellular targets that induce polyploidy and differentiation of AMKL blasts. In the initial chemical screen, several small molecule inducers of polyploidy were identified, including the lead compound dimethylfasudil (diMF). Through our multi-pronged target ID approach, we discovered that Aurora A was among the top scoring protein targets of diMF. Additional experiments demonstrated that inhibition by diMF and the Aurora A inhibitor MLN8237 (Alisertib) increase the polyploidization and differentiation of AMKL blasts. We further showed that inhibition of Aurora A with diMF led to a significant increase in survival of a mouse model of AMKL.
forty percent of the mice in the group treated with 66 mg/kg diMF and 30% of the mice treated with 33 mg/kg diMF survived long-term compared to a rapid lethal disease in the vehicle treated mice. A subsequent study by Mercher and colleagues modeled human pediatric AMKL in immunodeficient mice and found that small molecule Aurora A inhibition by MLN8237 could effectively treat a xenograft model of AMKL.

It has been hypothesized that the efficacy of Aurora kinase inhibitors as cancer therapeutics depends on their general antimitotic effects and it is unlikely that most tumors are specifically addicted to Aurora kinase activity. If this is true, Aurora kinase inhibitors mode of action may be different from other targeted therapies, like inhibitors of BCR–ABL or the HER2 oncoproteins that directly suppress proliferative signals. However, AMKL and malignancies with a prominent megakaryocyte role may be the exception. AMKL blasts appear to respond to Aurora A inhibition in a specific, targeted manner with terminal differentiation rather than a general antimitotic effect. This effect is analogous to targeted differentiation therapy in acute promyelocytic leukemia. The mechanism by which Aurora A inhibition selectively induces differentiation of megakaryocytic leukemia cells is unclear. One possibility is that the increase in differentiation is caused by decreased phosphorylation of a lineage specific transcription factor that controls terminal maturation and is active in the dephosphorylated state. Of note, consistent with an effect of Aurora A kinase inhibition on a megakaryocyte transcription factor, we have observed that megakaryocytes derived from murine bone marrow or human CD34+ cells also show increased differentiation with diMF or MLN8237 treatment. Non-malignant megakaryocytes also increase their ploidy state in response to Aurora A kinase inhibition. This may be associated with decreased Aurora kinase activity in maturing megakaryocytes.

CLINICAL TRIALS OF AURORA KINASE INHIBITORS

The first clinical trials with Aurora kinase inhibitors were launched in 2005 and at least seventy trials have been initiated to date to evaluate the clinical activity of these compounds. Aurora kinase inhibitors that have progressed through preclinical testing and into phase I or phase II trials include the Aurora A inhibitors MLN8054, PF-03814735, AS703569, MK-0457, MK-5108, MSC1992371A, and the Aurora B inhibitors AT9283 and PHA-739358 (Table 2). Recently, a number of studies have examined the activities of the Aurora A inhibitor MLN8237 and the Aurora B inhibitor AZD1152 (Barasertib).

Aurora A and B dual inhibitors

Preclinical and clinical studies have been performed with the combined Aurora kinase inhibitor VX-680 (Tozasertib) in chronic myelogenous leukemia (CML). VX-680 is a pan inhibitor of Aurora kinases with inhibition constant (Ki) values of 0.6, 18 and 4.6 nM for Aurora A, Aurora B and Aurora C, respectively. It was proven to be an efficacious inhibitor that decreased tumor growth in in vivo leukemia models. In one study, VX-680 was shown to inhibit growth, promote apoptosis, and reduce the phosphorylation of BCR-ABL in a CML cell line. Another preclinical study showed that in the KCL-22 CML cell line, inhibition of Aurora kinases with VX-680 sensitized CML cells to treatment with the BCR-ABL inhibitor imatinib and blocks acquisition of BCR-ABL mutations and relapse on imatinib. Additionally VX-680 showed activity in patients with the T315I mutation who
are resistant to BCR-ABL inhibitors such as imatinib\textsuperscript{133}. A CML clinical trial with VX-680 showed that it has activity in treating the disease with three patients achieving clinical responses\textsuperscript{133}. Unfortunately, development of VX-680 was terminated due to its severe toxicities. Another combined Aurora A/B inhibitor, AT9283, was shown to significantly inhibit the growth and survival of ALL patient cell lines\textsuperscript{134}. AT9283 was also shown to be effective at suppressing growth of CML and B-cell lymphoma cell lines\textsuperscript{135, 136}. A phase I dose-escalation study of a third combined Aurora A and B inhibitor MSC1992371A, was performed in patients with hematologic malignancies. Complete responses occurred in 3 patients. However, there was hematologic and gastrointestinal toxicity at clinically effective doses\textsuperscript{137}. Moreover, in two phase I trials of MSC1992371A in solid tumors the only responses seen were disease stabilization\textsuperscript{138, 139}.

**Aurora A inhibitors**

MLN8237 is an ATP-competitive, selective inhibitor of Aurora A (40-fold selective for Aurora A compared to Aurora B, IC50 4nM)\textsuperscript{128, 140}. Treatment of cells with MLN8237 causes defects in bipolar spindle assembly resulting in chromosomal segregation abnormalities. In addition, cells treated with Aurora A inhibitors arrest in mitosis due to activation of the mitotic checkpoint\textsuperscript{29, 47, 141}. The arrest is transient, and although inhibitors of Aurora A perturb the mitotic spindle, they do not cause a permanent mitotic arrest. After the initial mitotic arrest, treated cells exit mitosis, leading to aneuploidy and centrosome amplification\textsuperscript{142}. Although anti-Aurora A antibody injection studies have shown defects in completing cytokinesis, inhibition of Aurora A with small molecules was shown to not affect cytokinesis\textsuperscript{34, 142}. Aurora A inhibition phenotypes are similar to those observed upon its depletion by RNAi, underscoring that MLN8237 primarily targets Aurora A in vivo\textsuperscript{31}.

MLN8237 has proven to be effective in preclinical AML studies. Treatment of AML cell lines, primary AML cells and mouse models of AML with MLN8237 decreased their viability and colony forming ability on soft agar and increased their apoptosis. In addition, MLN8237 treatment was shown to potentiate the anti-leukemic activity of the standard chemotherapy cytarabine in both primary blasts and AML cell lines\textsuperscript{143}. A phase I/II clinical trial reported a 13% response rate for MLN8237 in relapsed and refractory AML patients. Additionally, in this clinical trial 11% of patients had a partial response and 49% of patients achieved stable disease\textsuperscript{144}.

Aurora A inhibitors have also been tested in CML in both preclinical and clinical studies. One preclinical study of Aurora A inhibitors in CML found that MLN8237 was effective at killing cells with the T315I mutation, which confers the greatest degree of resistance to approved targeted therapies, through a BCR-ABL independent mechanism\textsuperscript{145}. Inhibition of Aurora A with MLN8237 also significantly potentiated the in vitro and in vivo efficacy of the approved therapy nilotinib\textsuperscript{145}.

**Aurora B inhibitors**

Aurora B has been investigated as a potential target in leukemia for over 6 years after it was discovered that Aurora B is overexpressed in leukemia cells of ALL, AML and CLL patients\textsuperscript{54, 78, 146, 147}. AZD1152, the most often tested Aurora B inhibitor, is a pro-drug that

*Oncogene*. Author manuscript; available in PMC 2015 July 29.
undergoes phosphatase-mediated cleavage to release barasertib-hQPA, a selective Aurora B inhibitor \(^{90}\). In preclinical studies, treatment of AML cell lines and primary AML samples with AZD1152 reduced cell proliferation and increased cell death. In addition, AZD1152 decreased the growth of AML cell lines and primary AML in a xenotransplantation model \(^{148}\). These results were replicated in a two additional preclinical studies that showed that inhibition of Aurora B with AZD1152 inhibited proliferation and induced apoptosis of ALL and AML cells \(^{147,149}\). AZD1152 also appears to function synergistically with clinically approved leukemia therapies. In one preclinical study, AZD1152 synergistically enhanced the anti-proliferative effects of vincristine and daunorubicin in vitro and in vivo \(^{54}\). In a second study, treatment with AZD1152 and cytarabine together caused a greater than additive cytotoxicity in leukemic cells in vitro \(^{150}\).

AZD1152 has been tested in several phase I/II leukemia clinical trials with varying effectiveness. In one AML clinical trial, five patients with poor prognosis AML received AZD1152 and one entered complete remission \(^{90}\). In a different trial, 8 out of 32 AML patients had a hematologic response \(^{151}\). A similar overall hematologic response rate of 19\% was reported in a third study of 16 AML patients \(^{152}\). In a phase I/II trial testing AZD1152 versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia, a significant improvement (35.4\% vs. 11.5\%) in the response was observed in the AZD1152 group. The median OS was 8.2 months versus 4.5 months with cytosine arabinoside. However, AZD1152 did have a more toxic safety profile than cytosine arabinoside \(^{153}\). Due to its general anti-mitotic mechanism, myelosuppression and other side effects were a concern with the use of AZD1152. Preclinical studies treating human cord blood and mouse stem and progenitor cells with this agent showed that treatment results in inhibition of cell growth, apoptosis and delayed cell cycle progression both in vitro and in vivo \(^{148}\). In the clinical trials, the most common adverse events were neutropenia, febrile neutropenia and stomatitis/mucosal inflammation \(^{151,152}\). Although myelosuppression is the most common side effect of treatment with AZD1152, it is not a dose-limiting toxicity.

**Concluding remarks and perspectives**

In this review, we have highlighted the regulation and functions of each Aurora kinase, their involvement in leukemia and Aurora kinase inhibitor efficacy in leukemia clinical trials. Since the discovery of the Aurora kinases, extensive research into their function has identified key roles for each kinase in mitosis and cancer. These insights have led to the emergence of Aurora kinases as therapeutic targets in the treatment of leukemia. The combination of these targeted inhibitors with conventional cytotoxic therapies also shows promise. Studies in the next several years will likely focus on the further integration of Aurora kinase inhibitors into combinations with conventional therapies and will establish whether inhibition of Aurora A, Aurora B, or their combined inhibition is most effective. Going forward, challenges for researchers in the field include understanding if Aurora kinases are true oncogenic drivers and determining if it is possible to kill malignant cells by inhibiting Aurora kinases without disrupting the function and survival of non-cancerous cells. To date, tolerated doses of Aurora kinase inhibitors have not proven overly effective at treating leukemia in clinical trials. One potential breakthrough that could aid in this goal is the identification of specific cancers with heightened sensitivity to Aurora inhibition such as
AMKL. Uncovering other cancers dependent on Aurora kinase signaling could lead to effective killing of the malignant cells at doses that spare non-tumor cells.

Acknowledgments

We apologize to those whose work could not be discussed due to space limitations. This review was supported by grants from the NIH (R01s CA101774 and HL112792), the Samuel Waxman Cancer Research Foundation and the Leukemia and Lymphoma Society. B.G. is supported by the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Sciences (NCATS) (TL1R000108).

References

1. Glover DM, Leibowitz MH, McLean DA, Parry H. Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell. 1995; 81:95–105. [PubMed: 7720077]

2. Fu J, Bian M, Liu J, Jiang Q, Zhang C. A single amino acid change converts Aurora-A into Aurora-B-like kinase in terms of partner specificity and cellular function. Proc Natl Acad Sci U S A. 2009; 106:6939–6944. [PubMed: 19357306]

3. Hans F, Skoufias DA, Dimitrov S, Margolis RL. Molecular distinctions between Aurora A and B: a single residue change transforms Aurora A into correctly localized and functional Aurora B. Mol Biol Cell. 2009; 20:3491–3502. [PubMed: 19494039]

4. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003; 4:842–854. [PubMed: 14625535]

5. Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998; 17:3052–3065. [PubMed: 9606188]

6. Littlepage LE, Wu H, Andresson T, Deanehan JK, Amundadottir LT, Ruderman JV. Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci U S A. 2002; 99:15440–15445. [PubMed: 12422018]

7. Walter AO, Seghezzi W, Korver W, Sheung J, Lees E. The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene. 2000; 19:4906–4916. [PubMed: 11039908]

8. Ferrari S, Marin O, Pagano MA, Meggio F, Hess D, El-Shemerly M, et al. Aurora-A site specificity: a study with synthetic peptide substrates. Biochem J. 2005; 390:293–302. [PubMed: 16083426]

9. Haydon CE, Eyers PA, Aveline-Wolf LD, Riesen KA, Maller JL, Ahn NG. Identification of novel phosphorylation sites on Xenopus laevis Aurora A and analysis of phosphopeptide enrichment by immobilized metal-affinity chromatography. Mol Cell Proteomics. 2003; 2:1055–1067. [PubMed: 12885952]

10. Kimura M, Kotani S, Hattori T, Sumi N, Yoshioka T, Todokoro K, et al. Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J Biol Chem. 1997; 272:13766–13771. [PubMed: 9153231]

11. Kimura M, Uchida C, Takano Y, Kitagawa M, Okano Y. Cell cycle-dependent regulation of the human aurora B promoter. Biochem Biophys Res Commun. 2004; 316:930–936. [PubMed: 15033491]

12. Tanaka M, Ueda A, Kanamori H, Ideguchi H, Yang J, Kitajima S, et al. Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem. 2002; 277:10719–10726. [PubMed: 11790771]

13. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004; 101:6062–6067. [PubMed: 15075390]

14. Taguchi S, Honda K, Sugiura K, Yamaguchi A, Furukawa K, Urano T. Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Lett. 2002; 519:59–65. [PubMed: 12023018]
15. Nguyen HG, Chinnappan D, Urano T, Ravid K. Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol Cell Biol. 2005; 25:4977–4992. [PubMed: 15923616]

16. Arlot-Bonnemains Y, Klotzbucher A, Giet R, Uzbekov R, Bihan R, Prigent C. Identification of a functional destruction box in the Xenopus laevis aurora-A kinase pEg2. FEBS Lett. 2001; 508:149–152. [PubMed: 11707286]

17. Crane R, Kloepfer A, Ruderman JV. Requirements for the destruction of human Aurora-A. J Cell Sci. 2004; 117:5975–5983. [PubMed: 15536123]

18. Littlepage LE, Ruderman JV. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev. 2002; 16:2274–2285. [PubMed: 12208850]

19. Stewart S, Fang G. Destruction box-dependent degradation of aurora B is mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer Res. 2005; 65:8730–8735. [PubMed: 16204042]

20. Honda K, Mihara H, Kato Y, Yamaguchi A, Tanaka H, Yasuda H, et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex/ubiquitin-proteasome pathway. Oncogene. 2000; 19:2812–2819. [PubMed: 10851084]

21. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbe JC, Prigent C, Lorca T. APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep. 2002; 3:457–462. [PubMed: 11964384]

22. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, et al. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 2004; 432:775–779. [PubMed: 15592418]

23. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, et al. Chfr is required for tumor suppression and Aurora A regulation. Nat Genet. 2005; 37:401–406. [PubMed: 15793587]

24. Lim SK, Gopalan G. Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem J. 2007; 403:119–127. [PubMed: 17125467]

25. Shi F, Guo S, Dang Y, Qi M, Zhou G, Guo Z, et al. Human aurora-b binds to a proteasome alpha-subunit HC8 and undergoes degradation in a proteasome-dependent manner. Mol Cell Biochem. 2003; 254:157–162. [PubMed: 14674694]

26. Adams RR, Wheatley SP, Gouldsworth AM, Kandels-Lewis SE, Carmina M, Smythe C, et al. INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow. Curr Biol. 2000; 10:1075–1078. [PubMed: 10996078]

27. Vagnarelli P, Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma. 2004; 113:211–222. [PubMed: 15351889]

28. Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther. 2009; 8:2046–2056. [PubMed: 19584233]

29. Wysong DR, Chakravarty A, Hoat K, Ecsedy JA. The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle. 2009; 8:876–888. [PubMed: 19221504]

30. Musacchio A, Hardwick KG. The spindle checkpoint: structural insights into dynamic signalling. Nat Rev Mol Cell Biol. 2002; 3:731–741. [PubMed: 12360190]

31. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/ BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998; 20:189–193. [PubMed: 9771714]

32. Stenoien DL, Sen S, Mancini MA, Brinkley BR. Dynamic association of a tumor amplified kinase, Aurora-A, with the centrosome and mitotic spindle. Cell Motil Cytoskeleton. 2003; 55:134–146. [PubMed: 12740874]

33. Krystyniak A, Garcia-Echeverria C, Prigent C, Ferrari S. Inhibition of Aurora A in response to DNA damage. Oncogene. 2006; 25:338–348. [PubMed: 16158051]
34. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem. 2003; 278:51786–51795. [PubMed: 14523000]
35. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell. 2003; 114:585–598. [PubMed: 13678582]
36. Satinover DL, Brautigan DL, Stukenberg PT. Aurora-A kinase and inhibitor-2 regulate the cyclin threshold for mitotic entry in Xenopus early embryonic cell cycles. Cell Cycle. 2006; 5:2268–2274. [PubMed: 16969136]
37. Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature. 2008; 455:119–123. [PubMed: 18615013]
38. Seki A, Copping JA, Jang CY, Yates JR, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science. 2008; 320:1655–1658. [PubMed: 18566290]
39. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008; 1786:60–72. [PubMed: 18662747]
40. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci. 2007; 120:2987–2996. [PubMed: 17715155]
41. Bayliss R, Sardon T, Vernos I, Conté E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell. 2003; 12:851–862. [PubMed: 14580337]
42. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 1996; 135:1701–1713. [PubMed: 8991084]
43. Sunkel CE, Glover DM. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci. 1988; 89 (Pt 1):25–38. [PubMed: 3417791]
44. Petretti C, Savoian M, Montembault E, Glover DM, Prigent C, Giet R. The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. EMBO Rep. 2006; 7:418–424. [PubMed: 16462731]
45. Terada Y, Uetake Y, Kuriyama R. Interaction of Aurora-A and centrosomin at the microtubule-nucleating site in Drosophila and mammalian cells. J Cell Biol. 2003; 162:757–763. [PubMed: 12939255]
46. Toji S, Yabuta N, Hosomi T, Nishihara S, Kobayashi T, Suzuki S, et al. The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase. Genes Cells. 2004; 9:383–397. [PubMed: 15147269]
47. Mori D, Yano Y, Toyo-oka K, Yoshida N, Yamada M, Muramatsu M, et al. NDEL1 phosphorylation by Aurora-A kinase is essential for centrosomal maturation, separation, and TACC3 recruitment. Mol Cell Biol. 2007; 27:352–367. [PubMed: 17060449]
48. Giet R, McLean D, Descamps S, Lee MJ, Raff JW, Prigent C, et al. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J Cell Biol. 2002; 156:437–451. [PubMed: 11827981]
49. Terada Y. Role of chromosomal passenger complex in chromosome segregation and cytokinesis. Cell Struct Funct. 2001; 26:653–657. [PubMed: 11942622]
50. Lan W, Zhang X, Kline-Smith SL, Rosasco SE, Barrett-Wilt GA, Shabanowitz J, et al. Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Curr Biol. 2004; 14:273–286. [PubMed: 14972678]
51. Ohi R, Sapra T, Howard J, Mitchison TJ. Differentiation of cytoplasmic and meiotic spindle assembly MCAK functions by Aurora B-dependent phosphorylation. Mol Biol Cell. 2004; 15:2895–2906. [PubMed: 15064354]
52. Andrews PD, Ovechkina Y, Morrice N, Wagenbach M, Duncan K, Wordeman L, et al. Aurora B regulates MCAK at the mitotic centromere. Dev Cell. 2004; 6:253–268. [PubMed: 14960279]
53. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell. 2003; 14:3325–3341. [PubMed: 12925766]

Oncogene. Author manuscript; available in PMC 2015 July 29.
54. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007; 110:2034–2040. [PubMed: 17495131]

55. Goto H, Yasui Y, Kawajiri A, Nigg EA, Terada Y, Tatsuka M, et al. Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J Biol Chem. 2003; 278:8526–8530. [PubMed: 12458200]

56. Hirose K, Kawashima T, Iwamoto I, Nosaka T, Kitamura T. MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody. J Biol Chem. 2001; 276:5821–5828. [PubMed: 11085985]

57. Minoshima Y, Kawashima T, Hirose K, Tomozuka Y, Kawajiri A, Bao YC, et al. Phosphorylation by aurora B converts MgcRacGAP to a RhoGAP during cytokinesis. Dev Cell. 2003; 4:549–560. [PubMed: 12689593]

58. Kimura M, Matsuda Y, Yoshioka T, Okano Y. Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem. 1999; 274:7334–7340. [PubMed: 10066797]

59. Kimura M, Matsuda Y, Yoshioka T, Sumi N, Okano Y. Identification and characterization of STK12/Aik2: a human gene related to aurora of Drosophila and yeast IPL1. Cytogenet Cell Genet. 1998; 82:147–152. [PubMed: 9858806]

60. Li X, Sakashita G, Matsuzaki H, Sugimoto K, Kimura K, Hanaoka F, et al. Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C. J Biol Chem. 2004; 279:47201–47211. [PubMed: 15316025]

61. Sasai K, Katayama H, Stenoien DL, Fujii S, Honda R, Kimura M, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton. 2004; 59:249–263. [PubMed: 15499654]

62. Yan X, Cao L, Li Q, Wu Y, Zhang H, Saiyin H, et al. Aurora C is directly associated with Survivin and required for cytokinesis. Genes Cells. 2005; 10:617–626. [PubMed: 15938719]

63. Kimmins S, Crosio C, Kotaja N, Hirayama J, Monaco L, Hoog C, et al. Differential functions of the Aurora-B and Aurora-C kinases in mammalian spermatogenesis. Mol Endocrinol. 2007; 21:726–739. [PubMed: 17192404]

64. Dieterich K, Soto Rito R, Faure AK, Hennebicq S, Ben Amar B, Zahi M, et al. Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and causes male infertility. Nat Genet. 2007; 39:661–665. [PubMed: 17435757]

65. Peset I, Seiler J, Sardon LA, Rybina S, Vernos I. Function and regulation of Maskin, a TACC family protein, in microtubule growth during mitosis. J Cell Biol. 2005; 170:1057–1066. [PubMed: 16172207]

66. Liu Q, Ruderman JV. Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci U S A. 2006; 103:5811–5816. [PubMed: 16581905]

67. Marumoto T, Hirotta T, Morisaki T, Kunitoku N, Zhang D, Ichikawa Y, et al. Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells. 2002; 7:1173–1182. [PubMed: 12390251]

68. Hachet V, Canard C, Gonczy P. Centrosomes promote timely mitotic entry in C. elegans embryos. Dev Cell. 2007; 12:531–541. [PubMed: 17419992]

69. Portier N, Audhya A, Maddox PS, Green RA, Dammermann A, Desai A, et al. A microtubule-independent role for centrosomes and aurora a in nuclear envelope breakdown. Dev Cell. 2007; 12:515–529. [PubMed: 17419991]

70. Schumacher JM, Ashcroft N, Donovan PJ, Golden A. A highly conserved centrosomal kinase, AIR-1, is required for accurate cell cycle progression and segregation of developmental factors in Caenorhabditis elegans embryos. Development. 1998; 125:4391–4402. [PubMed: 9778499]

71. Lu LY, Wood HL, Ye L, Minter-Dykhouse K, Saunders TL, Yu X, et al. Aurora A is essential for early embryonic development and tumor suppression. J Biol Chem. 2008; 283:31785–31790. [PubMed: 18801727]
72. Cowley DO, Rivera-Perez JA, Schliekelman M, He YJ, Oliver TG, Lu L, et al. Aurora-A kinase is essential for bipolar spindle formation and early development. Mol Cell Biol. 2009; 29:1059–1071. [PubMed: 19075002]

73. Yoon Y, Cowley DO, Gallant J, Jones SN, Van Dyke T, Rivera-Perez JA. Conditional Aurora A deficiency differentially affects early mouse embryo patterning. Dev Biol. 2012; 371:77–85. [PubMed: 22939930]

74. Hegarat N, Smith E, Nayak G, Takeda S, Eyers PA, Hochegger H. Aurora A and Aurora B jointly coordinate chromosome segregation and anaphase microtubule dynamics. J Cell Biol. 2011; 195:1103–1113. [PubMed: 22184196]

75. Giet R, Glover DM. Drosophila aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J Cell Biol. 2001; 152:669–682. [PubMed: 11266459]

76. Fernandez-Miranda G, Trakala M, Martin J, Escobar B, Gonzalez A, Ghyselinck NB, et al. Genetic disruption of aurora B uncovers an essential role for aurora C during early mammalian development. Development. 2011; 138:2661–2672. [PubMed: 21613325]

77. Yang J, Ikezoe T, Nishioka C, Nobumoto A, Udaka K, Yokoyama A. CD34/CD38 acute myelogenous leukemia cells aberrantly express Aurora kinase A. Int J Cancer. 2013

78. Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vaddhan-Raj S, Fernandez MH, et al. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009; 2:2–8. [PubMed: 19669217]

79. Gu J, Gong Y, Huang M, Lu C, Spitz MR, Wu X. Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis. 2007; 28:350–355. [PubMed: 16926177]

80. Sakakura C, Hagiwara A, Yatsuoka R, Fujita Y, Nakanishi M, Masuda K, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer. 2001; 84:824–831. [PubMed: 11599099]

81. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003; 3:51–62. [PubMed: 12559175]

82. Tatsuka M, Sato S, Kojima S, Suto S, Kawai H, Mitsuhashi M, et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene. 2005; 24:1122–1127. [PubMed: 15592510]

83. Vernos I, Karsenti E. Chromosomes take the lead in spindle assembly. Trends Cell Biol. 1995; 5:297–301. [PubMed: 14732087]

84. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001; 2:21–32. [PubMed: 11414632]

85. Ke YY, Dou Z, Zhang J, Yao XB. Function and regulation of Aurora/lpllp kinase family in cell division. Cell Res. 2003; 13:69–81. [PubMed: 12737516]

86. Liu Q, Kaneko S, Yang L, Feldman RL, Nicosia SV, Chen J, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem. 2004; 279:52175–52182. [PubMed: 15469940]

87. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004; 36:55–62. [PubMed: 14702041]

88. Mao JH, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, et al. Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell. 2007; 11:161–173. [PubMed: 17292827]

89. Nair JS, Ho AL, Schwartz G. The induction of polyplody or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent. Cell Cycle. 2012; 11:807–817. [PubMed: 22293494]

90. Dennis M, Davies O, Oliver S, D’Souza R, Pike L, Stockman P. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother Pharmacol. 2012; 70:461–469. [PubMed: 22864876]
91. Nguyen HG, Makitalo M, Yang D, Chinnappan D, St Hilaire C, Ravid K. Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J. 2009; 23:2741–2748. [PubMed: 19332642]
92. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 2002; 62:5168–5177. [PubMed: 12234980]
93. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature. 2005; 437:1043–1047. [PubMed: 16222300]
94. Zekri A, Lesan V, Ghaffari SH, Tabrizi MH, Modarressi MH. Gene amplification and overexpression of Aurora-C in breast and prostate cancer cell lines. Oncol Res. 2012; 20:241–250. [PubMed: 23581231]
95. Tsou JH, Chang KC, Chang-Liao PY, Yang ST, Lee CT, Chen YP, et al. Aberrantly expressed AURKC enhances the transformation and tumourigenicity of epithelial cells. J Pathol. 2011; 225:243–254. [PubMed: 21710690]
96. Khan J, Ezan F, Cremet JY, Fautrel A, Gilot D, Lambert M, et al. Overexpression of active Aurora-C kinase results in cell transformation and tumour formation. PLoS One. 2011; 6:e26512. [PubMed: 22046298]
97. Vitrat N, Cohen-Solal K, Pique C, LeCouedic JP, Norol F, Larsen AK, et al. Endomitosis of human megakaryocytes are due to abortive mitosis. Blood. 1998; 91:3711–3723. [PubMed: 9573008]
98. Geddis AE, Fox NE, Tkachenko E, Kaushansky K. Endomitotic megakaryocytes that form a bipolar spindle exhibit cleavage furrow ingression followed by furrow regression. Cell Cycle. 2007; 6:455–460. [PubMed: 17312391]
99. Lordier L, Jalil A, Aurade F, Larbret F, Larghero J, Debili N, et al. Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood. 2008; 112:3164–3174. [PubMed: 18684864]
100. Geddis AE, Kaushansky K. Endomitotic megakaryocytes form a midzone in anaphase but have a deficiency in cleavage furrow formation. Cell Cycle. 2006; 5:538–545. [PubMed: 16552179]
101. Zhang Y, Sun S, Chen WC, Kaluzhny Y, Chinnappan D, Yu G, et al. Repression of AIM-1 kinase mRNA as part of a program of genes regulated by Mpl ligand. Biochem Biophys Res Commun. 2001; 282:844–849. [PubMed: 11401541]
102. Kawasaki A, Matsumura I, Miyagawa J, Ezoe S, Tanaka H, Terada Y, et al. Downregulation of an AIM-1 kinase couples with megakaryocytic polyploidization of human hematopoietic cells. J Cell Biol. 2001; 152:275–287. [PubMed: 11266445]
103. Zhang Y, Nagata Y, Yu G, Nguyen HG, Jones MR, Toselli P, et al. Aberrant quantity and localization of Aurora-B/AIM-1 and survivin during megakaryocyte polyploidization and the consequences of Aurora-B/AIM-1-deregulated expression. Blood. 2004; 103:3717–3726. [PubMed: 14751927]
104. Geddis AE, Kaushansky K. Megakaryocytes express functional Aurora-B kinase in endomitosis. Blood. 2004; 104:1017–1024. [PubMed: 15130946]
105. Lordier L, Chang Y, Jalil A, Aurade F, Garcon L, Lecluse Y, et al. Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. Blood. 2010; 116:2345–2355. [PubMed: 20548097]
106. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002; 32:148–152. [PubMed: 12172547]
107. Yoshida K, Toki T, Okuno Y, Kanekako R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013
108. Nikolaev SI, Santoni F, Vannier A, Falcomet E, Giarin E, Basso G, et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome. Blood. 2013; 122:554–561. [PubMed: 23733339]
109. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, et al. NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia.
with a distinct HOX gene expression pattern. Leukemia. 2013; 27:2280–2288. [PubMed: 23531517]

110. Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, et al. An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell. 2012; 22:683–697. [PubMed: 23153540]

111. Thiollier C, Lopez CK, Gerby B, Ignacimoutou C, Poglio S, Duffour Y, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med. 2012; 209:2017–2031. [PubMed: 23045605]

112. Mercher T, Raffel GD, Moore SA, Cornejo MG, Baudry-Bluteau D, Cagnard N, et al. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest. 2009; 119:852–864. [PubMed: 19287095]

113. Thiollier C, Lopez CK, Gerby B, Ignacimoutou C, Poglio S, Duffour Y, et al. Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med. 2012; 209:2017–2031. [PubMed: 23045605]

114. Wen Q, Goldenson B, Crispino JD. Normal and malignant megakaryopoiesis. Expert Rev Mol Med. 2011; 13:e32. [PubMed: 22018018]

115. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008; 112:4220–4226. [PubMed: 18755984]

116. Walters DK, Mercher T, Gu TL, O’Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006; 10:65–75. [PubMed: 16843266]

117. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia. 2007; 21:574–576. [PubMed: 17252020]

118. Leow S, Kham SK, Ariffin H, Quah TC, Yeoh AE. FLT3 mutation and expression did not adversely affect clinical outcome of childhood acute myeloid leukemia: a study of 531 Southeast Asian children by the Ma-Spore study group. Hematol Oncol. 2011; 29:211–219. [PubMed: 21387358]

119. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005; 106:3370–3373. [PubMed: 16037387]

120. Goldenson B, Crispino JD. Oncogene. Author manuscript; available in PMC 2015 July 29.

Oncogene. Author manuscript; available in PMC 2015 July 29.
128. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Leipsik M, Hajduch M. Aurora kinase inhibitors: Progress towards the clinic. Invest New Drugs. 2012; 30:2411–2432. [PubMed: 22350019]

129. Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama A, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther. 2007; 6:1851–1857. [PubMed: 17541033]

130. Howard S, Berdini V, Boustridge JA, Carr MG, Cross DM, Curry J, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2009; 52:379–388. [PubMed: 19143567]

131. Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013; 13:32. [PubMed: 23556431]

132. Yuan H, Wang Z, Zhang H, Roth M, Bhatia R, Chen WY. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Carcinogenesis. 2012; 33:285–293. [PubMed: 22116466]

133. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007; 109:500–502. [PubMed: 16990603]

134. Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, et al. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells. Leuk Lymphoma. 2013; 54:1505–1516. [PubMed: 23176524]

135. Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012; 130:2997–3005. [PubMed: 21796626]

136. Shah M, Gallipoli P, Lyons J, Holyoake T, Jorgensen H. Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. Blood Cells Mol Dis. 2012; 48:199–201. [PubMed: 22325915]

137. Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, et al. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. Leuk Res. 2013; 37:1100–1106. [PubMed: 23746966]

138. Raymond E, Alexandre J, Faivre S, Goldwasser F, Besse-Hammer T, Gianella-Borradori A, et al. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors. Invest New Drugs. 2013 Mar 29. Epub ahead of print.

139. Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, et al. A phase I study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol. 2013 Jul 6. Epub ahead of print.

140. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res. 2011; 17:7614–7624. [PubMed: 22016509]

141. Manfredi MG, Ecsedy JA, Meetez KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007; 104:4106–4111. [PubMed: 17360485]

142. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Roy N, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol. 2007; 27:4513–4525. [PubMed: 17438137]

143. Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, et al. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer. 2012; 131:2693–2703. [PubMed: 22488249]

144. Goldberg SLFP, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Leonard EJ, Fingert H, Westervelt P. Phase 2 study of MLN8237, an investigational Aurora A kinase
145. Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, et al. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011; 15:2057–2070. [PubMed: 21091633]

146. Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Mol Cancer. 2012; 11:42. [PubMed: 22721004]

147. Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica. 2008; 93:662–669. [PubMed: 18367484]

148. Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009; 69:4150–4158. [PubMed: 19366807]

149. Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013; 27:560–568. [PubMed: 22940834]

150. Yamauchi T, Uzui K, Shigemi H, Negoro E, Yoshida A, Ueda T. Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells. Cancer Sci. 2013; 104:926–933. [PubMed: 23557198]

151. Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011; 118:6030–6036. [PubMed: 21976672]

152. Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujiwara S, Yamauchi T, et al. A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res. 2011; 35:1384–1389. [PubMed: 21565405]

153. Kantarjian HM, Martinelli G, Jabbour EJ, Quintas-Cardama A, Ando K, Bay JO, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013; 119:2611–2619. [PubMed: 23605952]
Figure 1. Structure and domains of the aurora kinases
The Aurora kinases N-terminal and C-terminal domains contain D-box and KEN regulatory motifs while the central kinase domain contributes the catalytic activity. The central domain also includes key regulatory motifs such as the activation (T-loop) residue.
Figure 2. Aurora A and B are appropriately expressed and localized in mitosis
Aurora A localizes to the spindle poles, while Aurora B localizes to the midbody of the
central spindle during mitosis. Triangles, Aurora A kinase; Circles, Aurora B kinase; L-
shaped objects, centrosomes.
Figure 3. Aurora A and B are expressed and localized in endomitosis of megakaryocytes

Endomitotic cells are reported to show normal localization of both kinases \(^99, 104, 105\). The major difference from the proliferative cell cycle is the regression of the cleavage furrow, which leads to polyploidy \(^98–100\). Triangles, Aurora A kinase; Circles, Aurora B kinase; L-shaped objects, centrosomes.
Table 1

Aurora kinases exhibit different functions

| KINASE | FUNCTIONS                                           | REFERENCES  |
|--------|-----------------------------------------------------|-------------|
| AURKA  | Mitotic entry                                       | 26, 34–36, 47, 67, 74 |
|        | Chromosome alignment                               |             |
|        | Centrosome maturation                              |             |
|        | Centrosome separation                              |             |
|        | Spindle assembly checkpoint                        |             |
| AURKB  | Sister chromatid cohesion                          | 26, 50–53, 55 |
|        | Bipolar spindle assembly                            |             |
|        | Cytokinesis                                         |             |
|        | Spindle assembly checkpoint                        |             |
| AURKC  | Spermatogenesis                                     | 10, 59–64   |
|        | Chromosome segregation?                             |             |
|        | Cytokinesis?                                        |             |

(Oncogene. Author manuscript; available in PMC 2015 July 29.)
### Table 2

Aurora kinase inhibitors

| TARGET | MOLECULE          | PRECLINICAL ACTIVITY          | CLINICAL DEVELOPMENT | REFERENCES         |
|--------|-------------------|-------------------------------|----------------------|--------------------|
| AURORA A | MLN8237/MLN-8054 | Leukemia and solid tumors     | Phase II             | 111, 121, 128, 140–145 |
|        | MK-5108           | Solid tumors                  | Phase I              | 128                |
| AURORA B | AZD1152           | Leukemia and solid tumors     | Phase II             | 54, 147–153        |
|        | PHA-739358        | Leukemia and solid tumor      | Phase II             | 128, 146           |
| AURORA A AND B | VX-680/MK-0457 | Leukemia and solid tumors     | Terminated due to toxicity | 129, 131–133     |
|        | AT9283            | Leukemia and solid tumors     | Phase II             | 130, 134–136       |
|        | MSC1992371A       | Leukemia and solid tumors     | Phase I              | 137–139            |
|        | PF-03814735       | Solid tumors                  | Phase I              | 128                |
|        | AS703569          | Leukemia and solid tumor      | Phase I              | 128                |